

Lonza to establish new base in China using GE healthcare solution

14 December 2018 | News

New biologics facility, scheduled to be operational in 2020, will provide development and manufacturing facilities from early- to late-clinical and early-commercial stages.



Lonza has announced an agreement with GE Healthcare under which GE Healthcare will deliver a biologics facility to Lonza in Guangzhou, China. The new facility will give Lonza Pharma & Biotech a strategic base in China to respond to growing demand for high-quality CDMO services in the country.

By working with GE Healthcare to develop the new facility, based on the KUBio platform, an off-the-shelf biologics factory, Lonza intends to offer its suite of antibody development services and manufacture GMP-certified batches by 2020. The two companies will work closely on the design of the 17,000m² site, which will include 6,500 sq mtr of lab space and one KUBio facility.

The labs will house Lonza's proprietary platforms for cell-line construction, including the GS Gene Expression System®, as well as process development, cell banking and pilot labs. The KUBio unit will enable small-scale GMP manufacturing equipped with GE Healthcare's single-use biomanufacturing technologies, including 1,000 and 2,000L bioreactors, combined with Lonza's automation platforms for clinical and early-commercial supply.